ARCUTIS BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.63M, a 23.50% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $1.32M, a 103.24% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $649.00K, a 34.64% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $993.00K, a 1.74% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $2.38M, a 38.70% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.71M, a 45.79% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.18M, a 38.87% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.92M, a 128.27% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $2.38M 10-K · filed 2026-02-25 | |
| 2025-06-30 | $1.32M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $1.71M 10-K · filed 2026-02-25 | |
| 2024-06-30 | $649.00K 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $1.18M 10-K · filed 2026-02-25 | |
| 2023-06-30 | $993.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $1.92M 10-K · filed 2025-02-25 | |
| 2022-06-30 | $976.00K 10-Q · filed 2023-11-03 | |
| 2021-12-31 | $842.00K 10-K · filed 2024-02-27 | |
| 2021-06-30 | $478.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $617.00K 10-K · filed 2023-02-28 | |
| 2020-06-30 | $287.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |